Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)
posted on 2020-12-26, 10:00authored byMidas B. Mulder, Erwin Birnie, Caroline van Dijck – van Boetzelaer, Gert-Jan van de Geijn, Egbert Boevé, Elsbeth M. Westerman, Paul Hamberg
Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial)